Calls grow for China to bring in newer HCV therapies

A sharp drop in the price of hepatitis B therapy Viread (tenofovir) in China following negotiations sets the stage for a similar effort for cutting-edge hepatitis C therapies still not approved but nearing the finish line.

Earlier this year Viread, marketed in China by GlaxoSmithKline ($GSK) and developed by Gilead Sciences ($GILD), was one of three drugs that saw sharp price cuts after China's National Health and Family Planning Commission (NHFPC) worked out deals that would boost sales by getting them on the national reimbursement pricing list.

GSK CEO Andrew Witty on the second quarter earnings call said that Viread has made the list.

Free Daily Newsletter

Like this story? Subscribe to FiercePharma!

Biopharma is a fast-growing world where big ideas come along daily. Our subscribers rely on FiercePharma as their must-read source for the latest news, analysis and data on drugs and the companies that make them. Sign up today to get pharma news and updates delivered to your inbox and read on the go.

Cai Haodong, a professor of infectious diseases at Beijing’s Ditan Hospital, told the South China Morning Post that Viread now costs less than RMB500 ($75), down from RMB1,500 before the price talks.

And Bernhard Schwart­länder, the World Health Organization's representative in China, told the newspaper on World Hepatitis C day last week that affordability is the key for hepatitis C therapies as well.

“Only when a person can ­actually get these medicines--at an affordable price--will lives be saved,” he told the South China Morning Post. He added in a statement that about 10 million people living with chronic hepatitis in China face "mostly avoidable deaths" by 2030 unless Beijing acts.

Reports that some patients in China are mixing their own HCV therapies at home has also bolstered calls for quicker approvals. So far, Hangzhou-based biotech Ascletis Pharmaceuticals is in hot contention to get the first modern therapy approved in China, though Bristol Myers-Squibb ($BMY) and Gilead Sciences are also in approval processes nearing the end.

China is in talks with Gilead on pricing for HCV therapies--though it is not known if that includes Epclusa (sofosbuvir and velpatasvir), which is now available to 100 developing countries via a manufacturing and marketing license deal between Gilead and several Indian firms.

The deal does not cover China, which reportedly wants Gilead to charge a reference point not higher than that seen in 6 surrounding markets including India.

- here's the story from the South China Morning Post

Related Articles:
HCV drug price wars seen as Gilead confirms Indian firms to make Epclusa
Do-it-yourself hep C therapy emerges in China as cutting-edge approvals lag
China's Ascletis reports positive interim PhII on interferon-free HCV candidate
China wins major price cuts on patented drugs

Suggested Articles

Traditional generics bigwigs Teva, Mylan, Sandoz, Amneal and Endo have lost out to a group of six competitors in terms of U.S. weekly prescriptions.

Roche’s Tecentriq scored some big wins lately, including a pair of first-in-class approvals. But in other cancers, it's decided to pull the plug.

Biosims haven't worked, experts say. Instead, it's time to for an independent body to set fair biologic prices after the drugs lose exclusivity.